Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

被引:19
|
作者
Jones, Drew R. [1 ]
Miller, Grover P. [1 ]
机构
[1] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA
关键词
applications; metabolism; methods; warfarin; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHIRAL STATIONARY-PHASE; HUMAN LIVER-MICROSOMES; STABLE ISOTOPE ASSAY; SWEET CLOVER DISEASE; HUMAN-PLASMA; R-WARFARIN; MASS-SPECTROMETRY; S-WARFARIN; IN-VITRO;
D O I
10.1517/17425255.2011.576247
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Coumadin (R/S-warfarin) is the most widely prescribed oral anticoagulant in the world; nevertheless, its clinical use is complicated by unpredictability in dose requirements to achieve and maintain optimal anticoagulation. Variations in warfarin metabolism among patients contribute to unpredictability in therapeutic responses. Studying the clinical relevance of warfarin metabolism poses a significant analytical challenge. Warfarin is given to patients as an equal mixture of R and S enantiomers. Both drugs undergo extensive metabolism through different pathways to generate > 20 structurally similar isomeric metabolites. Areas covered: The article discusses how analytical methods have evolved to effectively resolve and quantify individual metabolites. The authors also discuss how the application of these methods has identified clinically relevant metabolic pathways for warfarin and fostered the investigation of clinical biomarkers for patient responses to therapy. The article additionally presents the power of these methods and how aspects of warfarin metabolism have led to the use of warfarin as a phenotyping probe for multiple drug metabolizing enzymes. Expert opinion: Progress in these areas has been hampered by shortcomings in analytical methods and a narrow focus on one metabolic pathway. Recent advances in liquid chromatographic-mass spectral methods can rapidly analyze most warfarin metabolites. It is now possible to effectively assess alternate metabolic pathways and expand biomarker analyses for clinical and phenotyping applications.
引用
收藏
页码:857 / 874
页数:18
相关论文
共 50 条
  • [1] What we know, what we don't know and what we need to know
    Chapple, Christopher R.
    MacNeil, Sheila
    CURRENT OPINION IN UROLOGY, 2019, 29 (04) : 378 - 379
  • [2] Quercetin and iron metabolism: What we know and what we need to know
    Xiao, Lin
    Luo, Gang
    Tang, Yuhan
    Yao, Ping
    FOOD AND CHEMICAL TOXICOLOGY, 2018, 114 : 190 - 203
  • [3] How to Succeed as an Athlete: What We Know, What We Need to Know
    Foster, Carl
    Barroso, Renato
    Beneke, Ralph
    Bok, Daniel
    Boullosa, Daniel
    Casado, Arturo
    Chamari, Karim
    Cortis, Cristina
    de Koning, Jos
    Fusco, Andrea
    Haugen, Thomas
    Lucia, Alejandro
    Mujika, Inigo
    Pyne, David
    Rodriguez-Marroyo, Jose A.
    Sandbakk, Oyvind
    Seiler, Stephen
    INTERNATIONAL JOURNAL OF SPORTS PHYSIOLOGY AND PERFORMANCE, 2022, 17 (03) : 333 - 334
  • [4] HOW WE KNOW WHAT WE KNOW
    KRAMER, P
    ETC-REVIEW OF GENERAL SEMANTICS, 1975, 32 (04): : 376 - 382
  • [5] Re: What we Know, What we Don't Know and What we Need to Know
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2020, 203 (06): : 1068 - 1068
  • [6] How Do We "Know" What We "Know?" And Change What We "Know?"
    Fosshage, James L.
    PSYCHOANALYTIC DIALOGUES, 2011, 21 (01) : 55 - 74
  • [7] HOW WE KNOW WHAT WE KNOW
    NOVACEK, M
    NATURAL HISTORY, 1995, 104 (06) : 28 - 29
  • [8] How we know what we know
    Collins, Harry
    NEW SCIENTIST, 2006, 192 (2581) : 46 - 48
  • [9] Diversity: What We Know, What We Need to Know, and What We Need to Do
    Dukes, Charles
    Lamar-Dukes, Pamela
    RESEARCH AND PRACTICE FOR PERSONS WITH SEVERE DISABILITIES, 2009, 34 (3-4) : 71 - 75
  • [10] Political Simulations: What We Know, What We Think We Know, and What We Still Need to Know
    Baranowski, Michael K.
    Weir, Kimberly A.
    JOURNAL OF POLITICAL SCIENCE EDUCATION, 2015, 11 (04) : 391 - 403